Patients' experiences and perceptions of chemotherapy-induced oral mucositis in a day unit.
Oral mucositis (OM) is a frequent and potentially severe complication of cancer chemotherapy. The aim of this descriptive, cross-sectional study was to better understand patients' experiences and perceptions of chemotherapy-induced OM. Fifty-seven adult patients in a chemotherapy day unit who had completed at least 2 cycles of chemotherapy within the previous 12 months and who were receiving chemotherapy at the time of study completed the questionnaire (response rate, 86.3%). Results demonstrated that 75.4% of participants (N = 57) had experienced at least one episode of OM since their first chemotherapy. Dry lips were the most common symptom of OM (n = 20, 54.1% previously; n = 14, 73.7% currently). Ulcerated mucosa was regarded as the most significant problem caused by OM (n = 14, 87.5% previously; n = 8, 100% currently), whereas pain on swallowing was considered as the most distressing mucositis-related effect (n = 14, 87.5% previously; n = 4, 100% currently). The findings revealed a high incidence of chemotherapy-induced OM. Chemotherapy-related mouth problems were perceived as problematic and caused varying degrees of distress. A systematic oral assessment method can be used in future studies with a cohort of patients to further generalize the pattern of patients' experiences of OM.
Chen
Hsiu-Mei
HM
Chang-Gung Institute of Technology, Taiwan. phsiumei@yahoo.com.tw
D000223:Adaptation, Psychological; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D003945:Diagnosis, Oral; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D016522:Oncology Service, Hospital; D017060:Patient Satisfaction; D010865:Pilot Projects; D011788:Quality of Life; D013280:Stomatitis / Q000139:chemically induced* / Q000523:psychology; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents